Pfizer Inc. (PFE)
Pfizer Inc. (PFE) is Attracting Investor Attention: Here is What You Should Know
Zacks.com users have recently been watching Pfizer (PFE) quite a bit. Thus, it is worth knowing the facts that could determine the stock's prospects.
New allegations about timing of Pfizer Covid vaccine passed to House panel
A former Pfizer scientist said the timing of the 2020 vaccine results “wasn't a coincidence,” according to allegations provided by a rival drugmaker.
EU court annuls rejection of bid for EU's von der Leyen vaccine messages with Pfizer
Europe's second-top court on Wednesday dismissed the European Commission's rejection of a New York Times' request to access text messages between its President Ursula von der Leyen and Pfizer CEO Albert Bourla on the purchase of billions of euros of COVID-19 vaccines.
PFE vs. LLY: Which Stock Is the Better Value Option?
Investors interested in stocks from the Large Cap Pharmaceuticals sector have probably already heard of Pfizer (PFE) and Eli Lilly (LLY). But which of these two companies is the best option for those looking for undervalued stocks?
Should Value Investors Buy Pfizer (PFE) Stock?
Here at Zacks, our focus is on the proven Zacks Rank system, which emphasizes earnings estimates and estimate revisions to find great stocks. Nevertheless, we are always paying attention to the latest value, growth, and momentum trends to underscore strong picks.
Pfizer (NYSE:PFE) Hasn't Been This Cheap in 13 Years. Time to Buy?
Pfizer (NYSE:PFE) is one of the world's largest pharmaceutical companies, but at $22.59 per share as of this writing, the stock trades at its lowest levels in 13 years.
Pfizer (PFE) Just Overtook the 20-Day Moving Average
From a technical perspective, Pfizer (PFE) is looking like an interesting pick, as it just reached a key level of support. PFE recently overtook the 20-day moving average, and this suggests a short-term bullish trend.
Can Pfizer (PFE) Climb 25.14% to Reach the Level Wall Street Analysts Expect?
The mean of analysts' price targets for Pfizer (PFE) points to a 25.1% upside in the stock. While this highly sought-after metric has not proven reasonably effective, strong agreement among analysts in raising earnings estimates does indicate an upside in the stock.
Pfizer Has Unreasonable Whiff Of The Marlboro Man
What makes Pfizer and Altria alike? They have trouble keeping their customers. Altria's dividend yield is 7%, even as it trades at 11 times estimated earnings over the next 12 months – a 40% premium to Pfizer. Pfizer, meanwhile, continues to provide life-saving treatments, while its dealmaking at least offers hope of future breakthroughs.
Pfizer Inc. (PFE) Is a Trending Stock: Facts to Know Before Betting on It
Zacks.com users have recently been watching Pfizer (PFE) quite a bit. Thus, it is worth knowing the facts that could determine the stock's prospects.
Pfizer Stock Up 5% Following Q1 Results: Time to Buy, Sell or Hold?
Investors may stay invested in PFE stock to see how its new growth drivers perform.
2 Wonderful Dividends At Bargain Basement Prices
Market pessimism creates opportunity. Pfizer and Rexford Industrial trade at historically low valuations, offering high dividend yields and strong long-term growth potential. Pfizer's diversified drug portfolio and promising oncology pipeline support its 7.1% yield and undervalued stock price. Rexford's focus on infill industrial properties in Southern California ensures steady growth. It's supported by a 5% yield and solid financials.
